Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Importance Amyloid positron emission tomography (PET) detects amyloid plaques in the
brain, a core neuropathological feature of Alzheimer disease. Objective To determine if …

Although systemic diseases take the biggest toll on human health and well-being,
increasingly, a failing brain is the arbiter of a death preceded by a gradual loss of the …

Possession of the ε4 allele of apolipoprotein E (APOE) is the primary genetic risk factor for
the sporadic form of Alzheimer's disease (AD). While researchers have extensively …

Abstract The Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) was
developed in the 1980s to assess the level of cognitive dysfunction in Alzheimer's disease …

Importance A National Institute on Aging–Alzheimer's Association (NIA-AA) workgroup
recently published a research framework in which Alzheimer disease is defined by …

Large phenotypically diverse research cohorts with both amyloid and tau PET have only
recently come into existence. Our objective was to determine relationships between the …

PURPOSE OF REVIEW Alzheimer disease (AD) is the most common cause of late-onset
dementia. This article describes the epidemiology, genetic and environmental risk factors …

The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may
reflect the fact that the enrolled participants in clinical trials are already too advanced to …